In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bioverativ Inc. (NASDAQ:BIVV) reported that Va Partners I, Llc has picked up 4,079,892 of common stock as of 2017-07-17.
The acquisition brings the aggregate amount owned by Va Partners I, Llc to a total of 4,079,892 representing a 3.8% in the company.
For those not familiar with the company, Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
A glance at Bioverativ Inc. (NASDAQ:BIVV)’s key stats reveals a current market capitalization of 60.71 Billion based on 160.16 Million shares outstanding and a price at last close of $60.71 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2017-05-30, Denner picked up 90,000 at a purchase price of $55.93. This brings their total holding to 1,165,000 as of the date of the filing.
On the sell side, the most recent transaction saw Duvall unload 818 shares at a sale price of $60.47. This brings their total holding to 2,128.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bioverativ Inc. (NASDAQ:BIVV) as things move forward to see if its progress aligns with these transactions.Subscribe below and we’ll keep you on top of what’s happening before it moves markets.